Sun Pharmaceutical Industries stock ended 2.15 per cent higher on Friday after zooming by almost 5 per cent in the morning trade on the back of an announcement that a court ruling has cleared the deck for the India's largest pharmaceutical company to launch its alopecia drug Leqselvi in the United States.
It affects men and women across all countries and ethnicities, with a lifetime risk of about two per cent.
Tackle your hair and skin problems with expert help from Dr Dinesh Jain.
'That is a significant milestone for us and something we aspired for.'
The best way is to combine relaxation techniques and a healthy balanced diet.
FDCI x Lakme Fashion Week is back with a promising line up of models.
It is believed to be Smith's first public appearance since his Oscars controversy.
'We want to express our deep gratitude to Mr Rock for maintaining his composure under extraordinary circumstances,' the Academy stated.
Sun Pharmaceutical Industries (Sun Pharma) reported a turnaround in the January-March quarter of the 2022-23 financial year (Q4FY23), declaring a profit after tax (PAT) of Rs 1,984 crore versus a loss of Rs 2,277 crore in Q4FY22. However, that loss in FY22 was due to several exceptional one-time items -- with Rs 3,723.15 crore allocated to settlement of lawsuits in the US and other Exceptional Items adding up to Rs 3,935.75 crore. Adjusted for exceptional items, PAT in Q4FY22 amounts to Rs 2,155 crore, which is a year-on-year (YoY) growth of about 36 per cent.
Bolstered by an impressive performance in the global specialty business and outstanding results in the Indian market, Sun Pharmaceutical Industries, the largest pharmaceutical (pharma) company in the country, showcased a strong performance in the July-September quarter (second quarter, or Q2) of 2023-24 (FY24).
Deficiencies in iron, protein and zinc can particularly lead to hair fall, warns dermatologist Dr Abhishek Pilani.
India's largest listed pharmaceutical (pharma) company - Sun Pharmaceutical Industries (Sun Pharma) - is expected to maintain its outperformance vis--vis the sector's, as its multiple bets on specialty products, improving product mix, recent acquisitions, and branded business are finding favour with brokerages. While it has gained 7 per cent over the past year, the Nifty Pharma Index is down 13.6 per cent. Its outperformance over two years has been fairly evident, with the market leader gaining 66 per cent to Nifty Pharma's minus 1.4 per cent.
Stress is one of the leading causes of premature greying, warns Dr Monica Chahar.
For all the glitz and glamour, politically and socially aware emphasis on representation and support for Ukraine, the 94th Annual Academy Awards was largely a bore.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances